 1. Patients must have a clinical and histopathologic diagnosis of GBM, have completed 80 of prescribed concurrent radiation therapy and adjuvant temozolomide without CTCEA grade 3 or 4 toxicity, and be greater than 7 months from the time of completion of concurrent chemoradiotherapy. 